Firebrick Pharma Limited
Firebrick Pharma Limited (FRE.AX) Stock Overview
Explore Firebrick Pharma Limited’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
15.3M
P/E Ratio
-7.96
EPS (TTM)
$-0.01
ROE
-0.95%
FRE.AX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Firebrick Pharma Limited (FRE.AX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 52.77, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.03.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -7.96 and a market capitalization of 15.3M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
Firebrick Pharma Limited engages in the development and commercialization of nasal spray treatment for the common cold under the Nasodine name in Australia. The company was incorporated in 2012 and is based in Melbourne, Australia.
Peter Laurence Molloy BSc, FAICD, MBA
440 Collins Street, Melbourne, VIC
2022